Gilead Sciences, Inc.

Clinton K Matson

Chandrasekar Venkataramani

Thomas F Kenney

The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.

Combination MCL-1 inhibitors with anti-cancer agents

The present disclosure generally relates to methods of treating or preventing cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate, and optionally one or more additional anti-cancer agents. In particular, the MCL-1 inhibitor can be a compound of formula (I), (II) or (III), or compound A. The antibody-drug conjugate can comprises an anti-Trop-2 antibody and an anti-cancer agent (e.g., SN-38). The combination therapy for treating cancer can have synergistic effect.

Growing community of inventors

Redmond, WA, United States of America

Clinton K Matson